HKU Scholars Hub: Browsing DSpace

Browsing by Author Gish, RG

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 20 of 23 next >

Title	Author(s)	Issue Date	Views
Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities Journal:Antiviral Research	Gish, RG Given, BD Lai, CL Locarnini, SA Lau, JYN Lewis, DL Schluep, T	2015	73
Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB Journal:Journal of Hepatology	Yuen, MF Locarnini S Lim, TH Strasser, SI Sievert W Cheng, W Thompson, AJ Given, BD Schluep, T Hamilton, J Biermer, M Kalmeijer, R Beumont, M Lenz, O De Ridder, F Cloherty, G Wong, DKH Schwabe, C Jackson, K Lai, CL Gish, RG Gane, E	14-Oct-2022
Differential reductions in viral antigens expressed from cccDNAVS integrated DNA in treatment naïve HBeAg positive and negative patients with chronic HBV after RNA interference therapy with ARC-520 Proceeding/Conference:Journal of Hepatology	Yuen, RMF Chan, HLY Liu, K Given, BD Schluep, T Hamilton, J Lai, CL Locarnini, SA Lau, JYN Ferrari, C Gish, RG	2016	88
Dose response with the RNA interference (RNAi) therapy JNJ-3989 combined with nucleos(t)ide analogue (NA) treatment in expanded cohorts of patients (pts) with chronic hepatitis B (CHB) Proceeding/Conference:Hepatology	Gane, EJ Locarnini, S Lim, TH Strasser, SI Sievert, W Cheng, W Thompson, A Given, BD Schluep, T Hamilton, J Biermer, M Kalmeijer, R Beumont-Mauviel, M Lenz, O Cloherty, G Wong, DKH Schwabe, C Jackson, K Ferrari, C Lai, CL Gish, RG Yuen, RMF	2019	41
Effective inhibition of cccDNA derived mRNA/viral antigens and tolerability with ARC-520 Proceeding/Conference:Hepatology International	Yuen, RMF Chan, HLY Liu, SHK Given, BD Schluep, T Hamilton, J Lai, CL Locarnini, SA Lau, JYN Ferrari, C Gish, RG	2016	61
Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C Journal:Gastroenterology	Sugauchi, F Orito, E Ichida, T Kato, H Sakugawa, H Kakumu, S Ishida, T Chutaputti, A Lai, CL Gish, RG Ueda, R Miyakawa, Y Mizokami, M	2003	192
First clinical experience with RNA interference [RNAI]-based triple combination therapy in chronic hepatitis B (CHB): JNJ-73763989 (JNJ-3989), JNJ-56136379 (JNJ-6379) and a nucleos(t)ide analogue (NA) Proceeding/Conference:Hepatology	Yuen, RMF Locarnini, S Given, B Schluep, T Hamilton, J Biermer, M Kalmeijer, R Beumont-Mauviel, M Lenz, O Cloherty, G Jackson, K Ferrari, C Lai, CL Liu, SHK Mak, LY Wong, DKH To, WP Ko, KL Gish, RG	2019	112
First results with RNA interference (RNAi) in chronic hepatitis b (CHB) using ARO-HBV Proceeding/Conference:Hepatology	Gane, EJ Locarnini, S Lim, TH Strasser, S Sievert, W Cheng, W Thompson, A Given, B Schluep, T Hamilton, J Li, Z Cloherty, G Wong, DKH Schwabe, C Jackson, K Ferrari, C Lai, CL Gish, RG Yuen, RMF	2018	83
Global multi-stakeholder endorsement of the MAFLD definition Journal:The Lancet Gastroenterology & Hepatology	Mendez-Sanchez, N Bugianesi, E Gish, RG Lammert, F Tilg, H Nguyen, MH Sarin, SK Fabrellas, N Zelber-Sagi, S Fan, JG Shiha, G Targher, G Zheng, MH Chan, WK Vinker, S Kawaguchi, T Castera, L Yilmaz, Y Korenjak, M Spearman, CW Ungan, M Palmer, M El-Shabrawi, M Gruss, HJ Dufour, JF Dhawan, A Wedemeyer, H George, J Valenti, L Fouad, Y Romero-Gomez, M Eslam, M Seto, Wai Kay Walter	7-May-2022
Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B Journal:Journal of Viral Hepatitis	Gish, RG Chang, TT Lai, CL De Man, R Gadano, A Poordad, F Yang, J BrettSmith, H Tamez, R	2010	91
Loss of HBsAg in nucleoside-naive HBeAg(+) chronic hepatitis B patients following treatment with entecavir or lamivudine: evaluation of HBV genotypes Proceeding/Conference:Hepatology	Gish, RG Chang, TT Lai, CL De Man, RA Poordad, F Xu, D Brett-Smith, H Harris, M Iloeje, U Tang, H	2009	59
Predicting HBsAg clearance responses during ARC-520 RNA interference (RNAi) therapy based on HBsAg epitope profile analysis Proceeding/Conference:Journal of Hepatology	Walsh, R Yuen, L Hammond, R Deerain, J Given, B Schluep, T Yuen, MF Chan, HLY Lai, CL Hamilton, J Lau, JY Ferrari, C Gish, RG Locarnini, SA	2016	69
Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen Proceeding/Conference:Journal of Hepatology	Yuen, RMF Liu, SHK Chan, HLY Given, BD Schluep, T Hamilton, J Lai, CL Locarnini, SA Lau, JY Ferrari, C Gish, RG	2017	63
Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive, nucleoside-naive patients treated with entecavir Journal:Antiviral Therapy	Gish, RG Chang, TT Lai, CL de Man, RA Gadano, A Llamoso, C Tang, H	2013	35
RNA Interference Therapy With ARC‐520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection Journal:Hepatology	Yuen, MF Schiefke, I Yoon, JH Ahn, SH Heo, J Kim, JH Chan, HLY Yoon, KT Klinker, H Manns, M Petersen, J Schluep, T Hamilton, J Given, BD Ferrari, C Lai, CL Locarnini, SA Gish, RG	2020	20
RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg Journal:Science Translational Medicine	Wooddell, CI Yuen, RMF Chan, HLY Gish, RG Locarnini, SA Chavez, D Ferrari, C Given, BD Hamilton, J Kanner, SB Lai, CL Lai, JYN Schluep, T Xu, Z Lanford, RE Lewis, DL	2017	32
Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers Journal:Clinical Pharmacology in Drug Development	Schluep, T Lickliter, J Hamilton, J Lewis, DL Lai, CL Lau, JYN Locarnini, SA Gish, RG Given, BD	2017	43
Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors Proceeding/Conference:Journal of Hepatology	Gane, E Locarnini, S Lim, TH Strasser, S Sievert, W Cheng, W Thompson, A Given, B Schluep, T Hamilton, J Biermer, M Kalmeijer, R Beumont-Mauviel, M Lenz, O De Ridder, F Cloherty, G Wong, DKH Schwabe, C Jackson, K Ferrari, C Lai, CL Gish, RG Yuen, RMF	2021	44
Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg < 100 IU/ml threshold Proceeding/Conference:Journal of Hepatology	Yuen, RMF Locarnini, S Lim, TH Strasser, S Sievert, W Cheng, W Thompson, A Given, B Schluep, T Hamilton, J Cloherty, G Wong, DKH Schwabe, C Jackson, K Ferrari, C Lai, CL Gish, RG Gane, E	2019	73
Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment Proceeding/Conference:Journal of Hepatology	Gane, E Locarnini, S Lim, TH Strasser, S Sievert, W Cheng, W Thompson, A Given, B Schluep, T Hamilton, J Biermer, M Kalmeijer, R Beumont-Mauviel, M Lenz, O Cloherty, G Wong, DKH Schwabe, C Jackson, K Ferrari, C Lai, CL Gish, RG Yuen, RMF	2020	78

Showing results 1 to 20 of 23 next >